The Current Ratio as of November 2024 (TTM) for Kronos Bio, Inc. (KRON) is 8.32

According to Kronos Bio, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 8.32. This represents a change of 2.79% compared to the average of 8.09 of the last 4 quarters.

Kronos Bio, Inc. (KRON) Historical Current Ratio (quarterly & annually)

How has KRON Current Ratio performed in the past?

The mean historical Current Ratio of Kronos Bio, Inc. over the last ten years is 19.90. The current 8.32 Current Ratio has changed 4.08% with respect to the historical average. Over the past ten years (40 quarters), KRON's Current Ratio was at its highest in in the March 2021 quarter at 35.91. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Kronos Bio, Inc. (KRON) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Kronos Bio, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kronos Bio, Inc. (KRON) Average Current Ratio

How has KRON Current Ratio performed in the past?

The current Current Ratio of Kronos Bio, Inc. (KRON) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Kronos Bio, Inc. (KRON) Current Ratio vs. Peers

How is KRON’s Current Ratio compared to its peers?

Kronos Bio, Inc.’s Current Ratio is greater than Cyclerion Therapeutics, Inc. (5.07), less than Larimar Therapeutics, Inc. (13.10), greater than Addex Therapeutics Ltd (4.97), greater than Achilles Therapeutics plc (6.04), less than NextCure, Inc. (9.07), greater than CytomX Therapeutics, Inc. (1.04), less than Neoleukin Therapeutics, Inc. (15.33), greater than Spero Therapeutics, Inc. (2.68), greater than Assembly Biosciences, Inc. (2.36), less than Replimune Group, Inc. (10.11), greater than Nuvectis Pharma, Inc. (2.74), greater than Lyra Therapeutics, Inc. (3.64), greater than Gossamer Bio, Inc. (6.74), less than Crinetics Pharmaceuticals, Inc. (16.38), greater than Inhibrx Biosciences, Inc. (4.70), less than Merus N.V. (8.32), less than Lyell Immunopharma, Inc. (13.43), greater than Generation Bio Co. (6.34), less than Erasca, Inc. (11.00), greater than C4 Therapeutics, Inc. (6.31), less than Edgewise Therapeutics, Inc. (26.35),

Build a custom stock screener for Kronos Bio, Inc. (KRON) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kronos Bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kronos Bio, Inc. (KRON) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kronos Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.